[{"address1": "260 Sheridan Avenue", "address2": "Suite 400", "city": "Palo Alto", "state": "CA", "zip": "94306", "country": "United States", "phone": "650 800 6676", "website": "https://vincerx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. The company is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with relapsed and refractory leukemia and lymphoid malignancies, as well as solid tumors and non-Hodgkin lymphoma; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat advanced or metastatic solid tumors. Its product candidates also include VIP943 in Phase 1 clinical trials for the treatment of relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia; and VIP924 in preclinical studies for the treatment of B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 and is based in Palo Alto, California.", "fullTimeEmployees": 42, "companyOfficers": [{"maxAge": 1, "name": "Dr. Ahmed M. Hamdy M.D.", "age": 58, "title": "Co-Founder, Chairman & CEO", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 657537, "exercisedValue": 0, "unexercisedValue": 12075}, {"maxAge": 1, "name": "Dr. Raquel E. Izumi Ph.D.", "age": 53, "title": "Co-Founder, President, COO, Secretary & Director", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 591540, "exercisedValue": 0, "unexercisedValue": 12075}, {"maxAge": 1, "name": "Mr. Alexander A. Seelenberger M.B.A.", "age": 44, "title": "Chief Financial Officer", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 491694, "exercisedValue": 0, "unexercisedValue": 11278}, {"maxAge": 1, "name": "Mr. Tom C. Thomas J.D.", "age": 63, "title": "Founder, General Counsel & Chief Legal Officer", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 444142, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John C. Byrd M.D.", "title": "Founder & Chairman of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hans-Georg  Lerchen Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Gabriela  Jairala", "title": "Sr Executive Director of Investor Relations & Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karen  Quarford", "title": "Vice President of Quality Operations & Compliance", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Melissa  Merrick SPHR", "title": "Senior Director of People & Culture and Head of Human Resource", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Beatrix  Stelte-Ludwig Ph.D.", "title": "Executive Chief Development Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.6599, "open": 0.65, "dayLow": 0.6409, "dayHigh": 0.7007, "regularMarketPreviousClose": 0.6599, "regularMarketOpen": 0.65, "regularMarketDayLow": 0.6409, "regularMarketDayHigh": 0.7007, "beta": 1.197, "forwardPE": -0.9082895, "volume": 114561, "regularMarketVolume": 114561, "averageVolume": 921533, "averageVolume10days": 215310, "averageDailyVolume10Day": 215310, "bid": 0.6858, "ask": 0.7023, "bidSize": 200, "askSize": 300, "marketCap": 20387458, "fiftyTwoWeekLow": 0.61, "fiftyTwoWeekHigh": 9.372, "fiftyDayAverage": 2.08112, "twoHundredDayAverage": 1.69146, "currency": "USD", "enterpriseValue": 6092677, "floatShares": 16848269, "sharesOutstanding": 29534200, "sharesShort": 1033567, "sharesShortPriorMonth": 799873, "sharesShortPreviousMonthDate": 1711584000, "dateShortInterest": 1714435200, "sharesPercentSharesOut": 0.035, "heldPercentInsiders": 0.19691, "heldPercentInstitutions": 0.35736, "shortRatio": 0.63, "shortPercentOfFloat": 0.044499997, "impliedSharesOutstanding": 29534200, "bookValue": 0.524, "priceToBook": 1.3173664, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -40157000, "trailingEps": -1.78, "forwardEps": -0.76, "enterpriseToEbitda": -0.143, "52WeekChange": -0.631016, "SandP52WeekChange": 0.22256601, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "VINC", "underlyingSymbol": "VINC", "shortName": "Vincerx Pharma, Inc.", "longName": "Vincerx Pharma, Inc.", "firstTradeDateEpochUtc": 1590586200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "46789548-9ff1-3829-9a39-73e43f85b2b7", "messageBoardId": "finmb_690173412", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.6903, "targetHighPrice": 10.0, "targetLowPrice": 4.0, "targetMeanPrice": 7.0, "targetMedianPrice": 7.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 12782000, "totalCashPerShare": 0.597, "ebitda": -42557000, "totalDebt": 2502000, "quickRatio": 2.511, "currentRatio": 2.629, "debtToEquity": 22.295, "returnOnAssets": -0.68722, "returnOnEquity": -1.3638, "freeCashflow": -24287624, "operatingCashflow": -40453000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-31"}]